T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis

Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Dec 8, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating a new way to quickly identify specific bacteria that cause serious infections in the spine and heart, known as pyogenic spondylodiscitis and infective endocarditis. The study uses a special test called the T2 Bacteria Panel, which looks for bacterial DNA in blood samples. It aims to find these infections faster and more accurately than traditional methods, which could help doctors start the right treatment sooner, improve patient outcomes, and reduce the risk of antibiotic resistance.

To participate in this trial, individuals must be diagnosed with either spondylodiscitis or infective endocarditis and should not have received antibiotics for more than 24 hours. Participants will have their blood tested using the new method, and their results will help researchers understand how well this test works compared to standard procedures. This study is currently recruiting participants of all genders, aged 65 and older, who can provide informed consent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of spondylodiscitis or/and facet joint infection or/and sacroileitis
• • Diagnosis of infective endocarditis
• • Antibiotic treatment not received or not longer than 24 hours
• • Ability to give informed consent
• Exclusion Criteria:
• • Spine infection or/and endocarditis not confirmed
• • Antibiotic treatment longer than 24 hours
• • Inability to give informed consent